TNGX

Tango Therapeutics, Inc.
CAPPED RATING

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Tango Therapeutics, Inc. (TNGX) is rated C (2.3/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B-); its weakest is Growth (D). The rating has held at C for 5 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.3 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
D
Factor Score 1.4 / 5.0
Profitability
C-
Factor Score 2.1 / 5.0
Momentum
B-
Factor Score 2.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -14.2
EV / EBITDA -14.9
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M 0.8%
Price Return 12M 232.5%
Catalyst Signal 0.00
Market Cap $4.3B
TTM Revenue $0.0
Price / Sales N/A
ROE -36.5%

Historical Factor Score Progression

Held C for 5 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 C+ (2.5) D (1.4) C- (2.1) B- (2.9) C+ (2.6) C (2.3)
2026-11-08 C+ (2.6) D (1.4) C+ (2.8) C+ (2.6) C+ (2.6) C (2.4)
2026-11-01 C+ (2.6) D (1.4) B- (2.9) B- (2.9) C+ (2.7) C (2.5)
2026-10-25 C+ (2.6) D (1.5) B- (2.9) C+ (2.5) C+ (2.6) C (2.4)
2026-10-18 C+ (2.6) D (1.4) B- (2.9) C (2.4) C+ (2.6) C (2.4)
Page 1 of 4